[go: up one dir, main page]

KR900000078A - 필수 지방산 조성물 - Google Patents

필수 지방산 조성물 Download PDF

Info

Publication number
KR900000078A
KR900000078A KR1019890007946A KR890007946A KR900000078A KR 900000078 A KR900000078 A KR 900000078A KR 1019890007946 A KR1019890007946 A KR 1019890007946A KR 890007946 A KR890007946 A KR 890007946A KR 900000078 A KR900000078 A KR 900000078A
Authority
KR
South Korea
Prior art keywords
acid
drug
formulation
efa
essential fatty
Prior art date
Application number
KR1019890007946A
Other languages
English (en)
Other versions
KR0129666B1 (ko
Inventor
프레드릭 호로빈 대비드
Original Assignee
스테판 제랄드 웨트모어
에파몰 홀딩스 피엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스테판 제랄드 웨트모어, 에파몰 홀딩스 피엘씨 filed Critical 스테판 제랄드 웨트모어
Publication of KR900000078A publication Critical patent/KR900000078A/ko
Application granted granted Critical
Publication of KR0129666B1 publication Critical patent/KR0129666B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

내용 없음

Description

필수 지방산 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (7)

  1. GLA와 n-6족 고급산에서 선택한 필수지방산 광, 스테아리돈산과 n-3족 고급산에서 선택된 필수지방산을 각산(each acid)10mg과 50g의 유효한 1일량으로 혼합시켜 정신분열증 및/또는 연합 지발성 운동장해를 처리하는 방법과 그 처리용 약물의 제제.
  2. 제1항에 있어서, 상기 n-6 EFA는 GLA, DGLA 및 AA에서 선택되고, 상기 n-3 EFA는 스테아리돈산, EPA, 22:5n-3및 DHA에서 선택됨을 특징으로한 상기 방법또는 약물의 제제.
  3. 제1항 또는 제2항에 있어서, 상기 EFAs에는 비타민 E를 상기산의 총량을 기준으로 하여 3wt%이상의 양으로 부가시킴을 특징으로 하는 상기 방법 또는 약물의 제제.
  4. 염증성분을 가진 피부질환을 처리하는 조성물, 방법 및 그 약물의 제제에 있어서, GLA와 n-6 족 고급산과 스테아리돈산 및 n-3조 고급산에서 선택된 필수지방산의 유효량은 상기 필수지방산을 기준으로하여 3wt%이상의 양으로 존재하는 비타민E를 국부제제에 혼합시킴을 특징으로 하는 상기 조성물, 방법 및 약물의 제제.
  5. 제4항에 있어서, 상기 n-6 과 n-3 의 EFA양자를 공존시킴을 특징으로 하는 상기 조성물, 방법 및 약물의 제제.
  6. 제5항에 있어서, 상기 n-6 EFA는 GLA, DGLA 및 AA에서 선택된, 상기 n-3 EFA는 스테아리돈산, EPA, 22:5n-3 및 DHA에서 선택함을 특징으로 하는 상기 조성물, 방법 또는 약물의 제제.
  7. 제4.,5 또는 제6항의 어느 한항에 있어서, 상기 염증질환은 과민성 급진, 건선, 좌창, 접촉피부염 또는 담마진임을 특징으로한 상기 조성물, 방법 또는 약물의 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890007946A 1988-06-10 1989-06-09 필수지방산 조성물 KR0129666B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB88-13766.6 1988-06-10
GB888813766A GB8813766D0 (en) 1988-06-10 1988-06-10 Essential fatty acid compositions

Publications (2)

Publication Number Publication Date
KR900000078A true KR900000078A (ko) 1990-01-30
KR0129666B1 KR0129666B1 (ko) 1998-04-09

Family

ID=10638418

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007946A KR0129666B1 (ko) 1988-06-10 1989-06-09 필수지방산 조성물

Country Status (13)

Country Link
US (2) US4977187A (ko)
EP (2) EP0347056B1 (ko)
JP (1) JP2796838B2 (ko)
KR (1) KR0129666B1 (ko)
AT (1) ATE87825T1 (ko)
AU (2) AU618814B2 (ko)
CA (1) CA1334004C (ko)
DE (1) DE68905863T2 (ko)
ES (1) ES2053990T3 (ko)
GB (1) GB8813766D0 (ko)
IE (1) IE63303B1 (ko)
NZ (1) NZ229423A (ko)
ZA (1) ZA894380B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물

Families Citing this family (113)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
US5407957A (en) * 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US6103755A (en) * 1990-05-22 2000-08-15 Bumann; Harold Foodstuff with prophylactic and/or healing effect and process for its production
DE69004081T2 (de) * 1990-05-23 1994-02-10 Nestle Sa Verwendung der Stearidonsäure zur Behandlung von Entzündungserkrankungen.
GB9012651D0 (en) * 1990-06-06 1990-07-25 Efamol Holdings Essential fatty acid treatment
GB9026648D0 (en) * 1990-12-07 1991-01-23 Efamol Holdings Nutrition
US5922345A (en) * 1990-12-07 1999-07-13 Scotia Holdings Plc Nutrition
AU661297B2 (en) * 1991-01-24 1995-07-20 Martek Corporation Microbial oil mixtures and uses thereof
US5663208A (en) * 1991-03-01 1997-09-02 Warner-Lambert Company Antifungal wound healing compositions and methods for preparing and using same
US5602183A (en) * 1991-03-01 1997-02-11 Warner-Lambert Company Dermatological wound healing compositions and methods for preparing and using same
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
US5646190A (en) * 1991-03-01 1997-07-08 Warner-Lambert Company Acne treating-wound healing compositions and methods for preparing and using same
US5692302A (en) * 1991-03-01 1997-12-02 Warner-Lambert Company Razor cartridges comprising wound healing compositions and methods for preparing and using same
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
US5633285A (en) * 1991-03-01 1997-05-27 Warner-Lambert Company Cytoprotective wound healing compositions and methods for preparing and using same
US5856364A (en) * 1991-03-01 1999-01-05 Warner Lambert Company Therapeutic antiviral-wound healing compositions and methods for preparing and using same
US5641814A (en) * 1991-03-01 1997-06-24 Warner-Lambert Company Antikeratolytic-wound healing compositions and methods for preparing and using same
US5674912A (en) * 1991-03-01 1997-10-07 Warner-Lambert Company Sunscreen-wound healing compositions and methods for preparing and using same
US5658956A (en) * 1991-03-01 1997-08-19 Warner-Lambert Company Bioadhesive-wound healing compositions and methods for preparing and using same
US5658957A (en) * 1991-03-01 1997-08-19 Warner Lambert Company Immunostimulating wound healing compositions and method for preparing and using same
US5863938A (en) * 1991-03-01 1999-01-26 Warner Lambert Company Antibacterial-wound healing compositions and methods for preparing and using same
US5614561A (en) * 1991-03-01 1997-03-25 Warner-Lambert Company Antihistamine-wound healing compositions and methods for preparing and using same
US5652274A (en) * 1991-03-01 1997-07-29 Martin; Alain Therapeutic-wound healing compositions and methods for preparing and using same
KR930006432B1 (ko) * 1991-04-10 1993-07-16 주식회사 우방랜드 아이코사펜타노산 및 α-리놀렌산을 함유하는 여드름 치료제 조성물
GB9112052D0 (en) * 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
FR2679109B1 (fr) * 1991-07-18 1994-03-11 Institut Recherche Biologique Sa Nouveaux complements nutritionnels ou dietetiques anti-vieillissement a base d'acide gras poly-insature.
JPH07114761B2 (ja) * 1991-08-29 1995-12-13 ジェクス株式会社 皮膚清拭用品
EP0567653A4 (en) * 1991-11-14 1994-06-01 Sagami Chem Res Drug for hepatic diseases
WO1993010776A1 (en) * 1991-11-26 1993-06-10 Warner-Lambert Company Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
US5260465A (en) * 1991-12-16 1993-11-09 Merck & Co., Inc. Inhibitors of farnesyl protein transferase
US5223285A (en) * 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
NL9201438A (nl) * 1992-08-11 1994-03-01 Prospa Bv Nieuwe farmaceutische samenstellingen die esters van omega-3 polyonverzadigde zuren omvatten en de toepassing ervan bij de plaatselijke behandeling van ziekelijke aandoeningen.
JPH0672868A (ja) * 1992-08-26 1994-03-15 Maruha Corp 抗精神病薬
GB9224809D0 (en) * 1992-11-26 1993-01-13 Scotia Holdings Plc Schizophrenia
GB9301446D0 (en) * 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
FR2704390B1 (fr) * 1993-04-29 1995-06-02 Boiron Complément nutritionnel absorbable per-os destiné à améliorer la peau.
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
DK0707487T3 (da) * 1993-06-09 2004-08-02 Martek Biosciences Corp Fremgangsmåder og farmaceutiske præparater, der er nyttige til behandling af neurologiske lidelser
DE4330664A1 (de) * 1993-09-10 1995-03-16 Beiersdorf Ag Verwendungen von Pflanzenölen
EP0734723A4 (en) * 1993-12-29 2001-04-11 Kowa Tekuno Sachi Co Ltd THERAPEUTIC COMPOSITION USEFUL FOR TREATING HYPERPARATHYROIDIA OF A PATIENT ON ARTIFICIAL DIALYSIS
CN1046499C (zh) * 1994-06-22 1999-11-17 旭化成工业株式会社 制备异丁烯醛的方法
AU711482B2 (en) * 1994-06-28 1999-10-14 Scotia Holdings Plc Compositions for treatment of diabetic complications
US6077828A (en) * 1996-04-25 2000-06-20 Abbott Laboratories Method for the prevention and treatment of cachexia and anorexia
CA2255615C (en) * 1996-05-22 2006-08-29 Neuromedica, Inc. Compositions comprising conjugates of cis-docosahexaenoic acid and docetaxel
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5919815A (en) * 1996-05-22 1999-07-06 Neuromedica, Inc. Taxane compounds and compositions
US6340485B1 (en) * 1996-06-03 2002-01-22 Croda International Plc Compositions and uses thereof
ES2203806T3 (es) * 1996-06-03 2004-04-16 Croda International Plc Compuestos y usos de los mismos.
GB9617847D0 (en) 1996-08-27 1996-10-09 Scotia Holdings Plc Fatty acid treatment
KR100657642B1 (ko) 1996-10-11 2006-12-19 스카리스타 리미티드 에이코사펜타엔산 및/또는 스테아리돈산을 포함하여 이루어지는 오일
WO1998048788A1 (en) * 1997-04-29 1998-11-05 Scotia Holdings Plc Treatment of depression and anxiety using docosahexaenoic acid or natural antioxidants
GB9724783D0 (en) 1997-11-24 1998-01-21 Inst Arable Crops Research Novel polypeptides
US6197764B1 (en) 1997-11-26 2001-03-06 Protarga, Inc. Clozapine compositions and uses thereof
FR2773075B1 (fr) 1997-12-31 2000-05-05 Cird Galderma Utilisation d'activateurs de ppar-gamma en dermatologie
US6225444B1 (en) 1998-02-10 2001-05-01 Protarga, Inc. Neuroprotective peptides and uses thereof
US7138431B1 (en) 1998-02-23 2006-11-21 Wake Forest University Dietary control of arachidonic acid metabolism
US6579551B1 (en) 1998-05-21 2003-06-17 Beech-Nut Nutrition Corporation Baby-food compositions containing egg yolk and methods therefor
US6149964A (en) * 1998-05-21 2000-11-21 Beech-Nut Nutrition Corporation Egg yolk-containing baby food compositions and methods therefor
US7141266B2 (en) * 1998-05-21 2006-11-28 Beech-Nut Nutrition Corporation Baby-food compositions enhancing visual acuity and methods therefor
US7413759B2 (en) * 1998-05-21 2008-08-19 Beech-Nut Nutrition Corporation Method of enhancing cognitive ability in infant fed DHA containing baby-food compositions
GB9901808D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Drugs for treatment of psychiatric and brain disorders
US7235583B1 (en) 1999-03-09 2007-06-26 Luitpold Pharmaceuticals, Inc., Fatty acid-anticancer conjugates and uses thereof
GB0016045D0 (en) * 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
US6506412B2 (en) 2000-11-29 2003-01-14 Sciencebased Health Treatment of dry eye syndrome
WO2002069964A1 (en) 2001-03-05 2002-09-12 Ernest Stephen P Enteral formulation
WO2002076402A2 (en) * 2001-03-23 2002-10-03 Protarga, Inc. Fatty amine drug conjugates
JP4634694B2 (ja) * 2001-03-23 2011-02-16 ルイトポルド・ファーマシューティカルズ・インコーポレーテッド 脂肪アルコール薬物複合体
EP1392623A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
EP1392278A4 (en) * 2001-05-14 2005-05-04 Martek Biosciences Corp PRODUCTION AND USE OF A LIPID-RICH POLAR FRACTION CONTAINING STEARIDONIC ACID AND GAMMA-LINOLENIC ACID EXTRACTED FROM SEEDS AND MICROORGANISMS
EP1285590A1 (en) * 2001-08-08 2003-02-26 Société des Produits Nestlé S.A. Lipid blends
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
FR2833174B1 (fr) * 2001-12-06 2004-05-28 Margaret Bronnert Pommade grasse d'origine animale destinee a soulager des demangeaisons et irritations de la peau dues aux dermites, eczema atopique et psoriasis,secheresse cutanee et hyperkeratinose
BR0308290A (pt) 2002-03-08 2005-01-11 Monsanto Technology Llc Tratamento e prevenção de distúrbios inflamatórios
WO2004004638A2 (en) * 2002-07-02 2004-01-15 Galileo Pharmaceuticals, Inc. Compositions and methods for reduction of inflammatory symptoms and/or biomarkers in female subjects
US7029712B1 (en) * 2002-07-17 2006-04-18 Biosyntrx Inc Treatment for dry eye syndrome
WO2004012753A1 (en) * 2002-07-31 2004-02-12 Helfried Hans Rudolf Crede Pharmaceutical composition containing black cumin oil, flax oil and borago oil
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US20160158261A1 (en) * 2002-10-25 2016-06-09 Foamix Pharmaceuticals Ltd. Antibiotic Kit and Composition and Uses Thereof
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US8173870B2 (en) 2003-08-21 2012-05-08 Monsanto Technology Llc Fatty acid desaturases from primula
US20070105954A1 (en) * 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
AU2005208832A1 (en) * 2004-01-19 2005-08-11 Martek Biosciences Corporation Reelin deficiency or dysfunction and methods related thereto
ITMI20040069A1 (it) 2004-01-21 2004-04-21 Tiberio Bruzzese Uso di composizioni di acidi grassi n-3 ad elevata concentrazione per il trattamento di disturbi del sistema nervoso centrale
BRPI0418634A (pt) * 2004-03-12 2007-05-29 Egis Gyogyszergyar Nyrt composição farmacêutica combinada para a inibição do declìnio das funções cognitivas
US7390507B2 (en) * 2004-04-13 2008-06-24 Ruwart Mary J Compositions and methods for the treatment of radiation burns and other traumatic skin conditions
WO2005102310A1 (en) 2004-04-16 2005-11-03 Monsanto Technology Llc Expression of fatty acid desaturases in corn
UY29195A1 (es) 2004-11-04 2006-06-30 Monsanto Technology Llc Procesos para la preparacion de composiciones oleosas
ITMI20051560A1 (it) * 2005-08-10 2007-02-11 Tiberio Bruzzese Composizione di acidi grassi n-3 con elevata concentrazione di epa e-o dha e contenente acidi grassi n-6
CN101500403A (zh) 2006-03-10 2009-08-05 孟山都技术有限责任公司 大豆种子和油的组成以及产生所述种子的方法
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
US8343753B2 (en) * 2007-11-01 2013-01-01 Wake Forest University School Of Medicine Compositions, methods, and kits for polyunsaturated fatty acids from microalgae
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
AU2015203289B2 (en) * 2008-09-09 2017-03-16 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
US20110166229A1 (en) * 2008-09-09 2011-07-07 Orygen Research Centre Prevention of psychotic disorders and/or treatment of psychotic symptoms
WO2010125470A2 (en) 2009-04-28 2010-11-04 Foamix Ltd. Foamable vehicle and pharmaceutical compositions comprising aprotic polar solvents and uses thereof
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
US9480271B2 (en) 2009-09-15 2016-11-01 Monsanto Technology Llc Soybean seed and oil compositions and methods of making same
CA2776471C (en) 2009-10-02 2019-02-12 Foamix Ltd. Surfactant-free, water-free, foamable compositions and breakable foams and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US9119826B2 (en) 2011-02-16 2015-09-01 Pivotal Therapeutics, Inc. Omega 3 fatty acid for use as a prescription medical food and omega 3 fatty acid diagniostic assay for the dietary management of cardiovascular patients with cardiovascular disease (CVD) who are deficient in blood EPA and DHA levels
US8952000B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Cholesterol absorption inhibitor and omega 3 fatty acids for the reduction of cholesterol and for the prevention or reduction of cardiovascular, cardiac and vascular events
US8951514B2 (en) 2011-02-16 2015-02-10 Pivotal Therapeutics Inc. Statin and omega 3 fatty acids for reduction of apolipoprotein-B levels
US8715648B2 (en) 2011-02-16 2014-05-06 Pivotal Therapeutics Inc. Method for treating obesity with anti-obesity formulations and omega 3 fatty acids for the reduction of body weight in cardiovascular disease patients (CVD) and diabetics
US20120252888A1 (en) 2011-03-29 2012-10-04 Palupa Medical Ltd. Compositions and Methods for Treating Neurologic Disorders
JPWO2012153832A1 (ja) 2011-05-12 2014-07-31 日本水産株式会社 炎症性疾患用皮膚外用組成物
US8728546B1 (en) 2013-03-15 2014-05-20 Swing Aerobics Licensing, Inc. Medicament for treatment of cancer, cardiovascular diseases and inflammation
EP3101138B1 (en) 2013-12-04 2021-05-05 Nippon Suisan Kaisha, Ltd. Microbial oil, method for manufacturing microbial oil, concentrated microbial oil, and method for manufacturing concentrated microbial oil
MX377365B (es) 2016-09-08 2025-03-10 Journey Medical Corp Composiciones y métodos para tratar rosácea y acné.
EP4384157A1 (en) 2021-08-09 2024-06-19 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1082624A (en) * 1965-02-26 1967-09-06 Calmic Ltd Improvements in or relating to therapeutically active compounds
US4273763A (en) * 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
GB8302708D0 (en) * 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
CA1239587A (en) * 1983-10-24 1988-07-26 David Rubin Combined fatty acid composition for lowering blood cholestrol and triglyceride levels
IT1176916B (it) * 1984-10-10 1987-08-18 Elvira Pistolesi Composizione farmaceutica o dietetica ad elevata attivita' antitrombotica e antiarteriosclerotica
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
US4738985A (en) * 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
DE3644677A1 (de) * 1986-12-30 1988-07-14 Mohamed Roshdy Dr Ismail Mittel zur verbesserung der bluteigenschaft
DE3719097C1 (de) * 1987-06-06 1988-06-09 Fratzer Uwe Arzneimittel,enthaltend Eicosapentaensaeure und Docosahexaensaeure als ungesaettigte Fettsaeuren sowie Vitamin E
GB8714772D0 (en) * 1987-06-24 1987-07-29 Efamol Ltd Essential fatty acid compositions
GB8813766D0 (en) * 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100580070B1 (ko) * 2004-07-07 2006-05-16 주식회사 엘지생활건강 피부 미백용 식품 조성물

Also Published As

Publication number Publication date
ES2053990T3 (es) 1994-08-01
AU7943491A (en) 1991-09-12
NZ229423A (en) 1992-10-28
AU3597489A (en) 1989-12-14
AU633442B2 (en) 1993-01-28
EP0347056B1 (en) 1993-04-07
EP0347056A1 (en) 1989-12-20
KR0129666B1 (ko) 1998-04-09
EP0454102A2 (en) 1991-10-30
JPH0232017A (ja) 1990-02-01
DE68905863T2 (de) 1993-08-26
JP2796838B2 (ja) 1998-09-10
EP0454102A3 (en) 1992-01-02
AU618814B2 (en) 1992-01-09
US4977187A (en) 1990-12-11
IE891819L (en) 1989-12-10
US5120760A (en) 1992-06-09
ATE87825T1 (de) 1993-04-15
ZA894380B (en) 1990-02-28
IE63303B1 (en) 1995-04-05
GB8813766D0 (en) 1988-07-13
CA1334004C (en) 1995-01-17
DE68905863D1 (de) 1993-05-13

Similar Documents

Publication Publication Date Title
KR900000078A (ko) 필수 지방산 조성물
DE3926658C2 (de) Fettsäurezusammensetzung
JP4861606B2 (ja) 皮膚炎を治療するプロアントシアニジンを含む局所用医薬組成物
DE69100724T2 (de) Zusammensetzungen essentieller Fettsäuren und Therapie.
DE69534536T2 (de) Verwendung zur topischen anwendung von tocotrienol auf die haut und haare
DE68911103T2 (de) Verwendung von Fettsäuren zur Behandlung von myalgischer Enzephalomyelitis.
DE3486339T2 (de) Pharmazeutische und diätetische Zusammensetzung.
DE69312579T2 (de) Arzneimittel zur Behandlung von Vulva-Dystrophie oder Vaginaltrockenheit
DE3634152C2 (de) Neue kosmetische oder dermatologische Zusammensetzungen, die reich sind an gleichzeitig in Form der Triglyceride und in freier Form oder Salzform vorliegenden, essentiellen Fettsäuren
KR940021057A (ko) 흡연의 악영향을 완화시키기 위한 조성물
DE69720737T3 (de) Pflanzliche ölzusammensetzungen
DE69114498D1 (de) Kurzbettige, einfach ungesättigte fettsäuren enthaltende nahrungsmittel und pharmazeutische zusammensetzungen sowie deren anwendungen.
DE69806962T2 (de) FSNMU als entzündungshemmende Mittel in den oberflächen Geweben von Säugetieren
AU595012B2 (en) Iron - containing composition and method for treatment of cancer
US5145686A (en) Topical pharmaceutical compositions
ATE258792T1 (de) Diät mit hohem lipidgehalt
DE69005062T2 (de) Fettsäuren zur Behandlung und Prävention von Hautschäden durch Radiotherapie.
DE69118130T2 (de) Nahrung
DE1492149A1 (de) Masse zur Behandlung und zur Pflege der Haut
DE602004004880T2 (de) Hautpflegeprodukt mit tallöl-fettsäuren und pflanzenölen für trockene und schuppende haut und behandlung von psoriasis, dermatitis und ekzemen
DE4238869C2 (de) Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
EP1799204B1 (de) Omega-3-fettsäuren und omega-6-fettsäuren enthaltende zusammensetzung
DE4330664A1 (de) Verwendungen von Pflanzenölen
IE58919B1 (en) Pharmaceutical and dietary composition
EP1430891A1 (de) Öl-Säure-Emulsion zur Behandlung von Gelenkerkrankungen und zur Durchblutungsanregung

Legal Events

Date Code Title Description
PA0109 Patent application

Patent event code: PA01091R01D

Comment text: Patent Application

Patent event date: 19890609

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19940121

Comment text: Request for Examination of Application

Patent event code: PA02011R01I

Patent event date: 19890609

Comment text: Patent Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 19970521

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 19970920

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 19971112

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 19971112

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20001102

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20011107

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20021106

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20031106

Start annual number: 7

End annual number: 7

FPAY Annual fee payment

Payment date: 20041109

Year of fee payment: 8

PR1001 Payment of annual fee

Payment date: 20041109

Start annual number: 8

End annual number: 8

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

Termination category: Default of registration fee

Termination date: 20061010